Bernhard's main focus lies in the drafting and handling of patents in the areas of electric engineering, software inventions as well as devices for biotechnology and optics. Furthermore he possesses great experience in opposition cases and IP litigation cases as well as trade mark protection.
Bernhard studied Applied Physics at the Technical University of Munich. He has been in the IP business since 1990. He was accredited as a German Patent Attorney in 1994 and in the same year also qualified as a European Patent Attorney.
He has made his name as a specialist legal author with, amongst others, with the article “Patent situation in the field of DNA chip technology in Europe” (which appeared in no. 12/2000 of medgen, the newsletter of the German Association for Human Genetics) and the article “Is the core theory once again topical?” (which appeared in the Transactions of German Patent Attorneys in December 2003), dealing with German case law in respect of software inventions. This article was cited by the Enlarged Board of Appeal in the up to now only decision (G 03/08) relating to computer implemented inventions. He regularly gives lectures on different topics in IP law.
Bernhard is a member of the Licensing Executive Society (LES) and the European Patent Experts Exchange (EuPEX).
Medical Technology Ireland Conference 2022 will be held on 21-22 September at the Galway Racecource. Medical Technology Ireland is a new high-profile National and International event attracting global suppliers to …Event details
Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …Read article
Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder . …Read article
Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …Read article
Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …Read article
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.